Reduction of the ganglioside binding activity of the tetanus toxin H C fragment destroys immunogenicity: Implications for development of novel tetanus vaccines

Infection and Immunity

Volumn 74, Issue 8, 2006, Pages 4884-4891

  Qazi, Omar ^a   Sesardic, Dorothea ^b   Tierney, Robert ^b   Söderbäck, Zahra ^b   Crane, Dennis ^b   Bolgiano, Barbara ^b   Fairweather, Neil ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE; NEUROTOXIN; TETANUS TOXIN; TETANUS TOXOID;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CELL PROTECTION; CIRCULAR DICHROISM; CLOSTRIDIUM TETANI; FLUORESCENCE SPECTROSCOPY; GENE DELETION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TETANUS; WILD TYPE;

ANIMALS; ANTIBODIES, BACTERIAL; FEMALE; GANGLIOSIDES; GENE DELETION; IMMUNIZATION; MICE; PEPTIDE FRAGMENTS; TETANUS; TETANUS TOXIN; TETANUS TOXOID; TOXINS, BIOLOGICAL;

EID: 33746639618     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00500-06     Document Type: Article

References (32)

1. Andersen, R., X. M. Gao, A. Papakonstantinopoulou, M. Roberts, and G. Dougan. 1996. Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Infect. Immun. 64:3168-3173.
2. Chatfield, S. N., N. Fairweather, I. Charles, D. Pickard, M. Levine, D. Hone, M. Posada, R. A. Strugnell, and G. Dougan. 1992. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine 10:53-60.
3. Coen, L., R. Osta, M. Maury, and P. Brulet. 1997. Construction of hybrid proteins that migrate retrogradely and transynaptically into the central nervous system. Proc. Natl. Acad. Sci. USA 94:9400-9405.
4. Dietz, V., J. B. Milstien, F. van Loon, S. Cochi, and J. Bennett. 1996. Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus. Bull. W. H. O. 74:619-628.
5. Douce, G., M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:2821-2828.
6. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644-1648.
7. Due, L. H., H. A. Hong, N. Fairweather, E. Ricca, and S. M. Cutting. 2003. Bacterial spores as vaccine vehicles. Infect. Immun. 71:2810-2818.
8. Emsley, P., C. Fotinou, I. Black, N. F. Fairweather, I. G. Charles, C. Watts, E. Hewitt, and N. W. Isaacs. 2000. The structures of the H(C) fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding. J. Biol. Chem. 275:8889-8894.
9. Fairweather, N. F., S. N. Chatfield, A. J. Makoff, R. A. Strugnell, J. Bester, D. J. Maskell, and G. Dougan. 1990. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier. Infect. Immun. 58:1323-1326.
10. Farrar, J. J., L. M. Yen, T. Cook, N. Fairweather, N. Binh, J. Parry, and C. M. Parry. 2000. Tetanus. J. Neurol. Neurosurg. Psychiatry 69:292-301.
11. Fishman, P. S., and D. R. Carrigan. 1987. Retrograde transneuronal transfer of the C-fragment of tetanus toxin. Brain Res. 406:275-279.
12. Fotinou, C., P. Emsley, I. Black, H. Ando, H. Ishida, M. Kiso, K. A. Sinha, N. F. Fairweather, and N. W. Isaacs. 2001. The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J. Biol. Chem. 276:32274-32281.
13. Herreros, J., G. Lalli, and G. Schiavo. 2000. C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor. Biochem. J. 347:199-204.
14. Ho, M. M., B. Bolgiano, and M. J. Corbel. 2000. Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines. Vaccine 19:716-725.
15. Kabsch, W., and C. Sander. 1983. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22:2577-2637.
16. King, S. M., and W. C. Johnson. 1999. Assigning secondary structure from protein coordinate data. Proteins 35:313-320.
17. Lalli, G., J. Herreros, S. L. Osborne, C. Montecucco, O. Rossetto, and G. Schiavo. 1999. Functional characterisation of tetanus and botulinum neurotoxins binding domains. J. Cell Sci. 112:2715-2724.
18. Mach, H., C. R. Middaugh, and R. V. Lewis. 1992. Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. Anal. Biochem. 200:74-80.
19. Makoff, A. J., S. P. Ballantine, A. E. Smallwood, and N. F. Fairweather. 1989. Expression of tetanus toxin fragment C in E. coli: its purification and potential as a vaccine. Bio/Technology 7:1043-1046.
20. Manavalan, P., and W. C. Johnson, Jr. 1987. Variable selection method improves the prediction of protein secondary structure from circular dichroism spectra. Anal. Biochem. 167:76-85.
21. Montecucco, C., and G. Schiavo. 1993. Tetanus and botulism neurotoxins: a new group of zinc proteases. Trends Biochem. Sci. 18:324-327.
22. Robbins, J. B., R. Schneerson, B. Trollfors, H. Sato, Y. Sato, R. Rappuoll, and J. M. Keith. 2005. The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J. Infect. Dis. 191:81-88.
23. Rummel, A., S. Bade, J. Alves, H. Bigalke, and T. Binz. 2003. Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity. J. Mol. Biol. 326:835-847.
24. Schiavo, G., F. Benfenati, B. Poulain, O. Rossetto, P. Polverino de Laureto, B. R. DasGupta, and C. Montecucco. 1992. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359:832-835.
25. Sinha, K., M. Box, G. Lalli, G. Schiavo, H. Schneider, M. Groves, G. Siligardi, and N. Fairweather. 2000. Analysis of mutants of tetanus toxin HC fragment: ganglioside binding, cell binding and retrograde axonal transport properties. Mol. Microbiol. 37:1041-1051.
26. Sreerama, N., and R. W. Woody. 1994. Protein secondary structure from circular dichroism spectroscopy. Combining variable selection principle and cluster analysis with neural network, ridge regression and self-consistent methods. J. Mol. Biol. 242:497-507.
27. Sreerama, N., and R. W. Woody. 1993. A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal. Biochem. 209:32-44.
28. Tacket, C. O., J. Galen, M. B. Sztein, G. Losonsky, T. L. Wyant, J. Nataro, S. S. Wasserman, R. Edelman, S. Chatfield, G. Dougan, and M. M. Levine. 2000. Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol. 97:146-153.
29. Tierney, R., A. S. Beignon, R. Rappuoli, S. Muller, D. Sesardic, and C. D. Partidos. 2003. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J. Infect. Dis. 188:753-758.
30. Tregoning, J. S., P. Nixon, H. Kuroda, Z. Svab, S. Clare, F. Bowe, N. Fairweather, J. Ytterberg, K. J. van Wijk, G. Dougan, and P. Maliga. 2003. Expression of tetanus toxin fragment C in tobacco chloroplasts. Nucleic Acids Res. 31:1174-1179.
31. Umland, T. C., L. M. Wingert, S. Swaminathan, W. F. Furey, J. J. Schmidt, and M. Sax. 1997. Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat. Struct. Biol 4:788-792.
32. Xing, D. K. L., K. McLellan, M. J. Corbel, and D. Sesardic. 1996. Estimation of antigenic tetanus toxoid extracted from biodegradable microspheres. Biologicals 24:57-65.